amifampridine phosphate
CMS-001
Phase 3 small_molecule completed
Quick answer
amifampridine phosphate for Myasthenic Syndromes, Congenital is a Phase 3 program (small_molecule) at CATALYST PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CATALYST PHARMACEUTICALS, INC.
- Indication
- Myasthenic Syndromes, Congenital
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed